

---

**FAROUK A. AWAD, M.D.**

---

**Education & Training**

Undergraduate	BS in Science Baghdad University - College of Medicine	<b>1980-1983</b>
Medical School	Medical Degree Baghdad University - College of Medicine	<b>1983-1986</b>
Residency	Pediatric Medicine Baghdad Pediatric Hospital	<b>1986-1987</b>
	General Surgery Emergency Surgical Center	<b>1986-1987</b>
	Internal Medicine Al Numan General Hospital	<b>1986-1987</b>
Continuing Education	Internal and External Audit Course University of California, San Diego	<b>1998</b>
	Child, Infant and Adult CPR American Red Cross	<b>2000-2005</b>

**Employment History**

**Clinical Research Manager** **09/2004 to Present**  
Core Orthopaedic Medical Center, Encinitas, California

**Independent Consulting Services** **02/2004 to 09/2004**  
San Dieguito Orthopedic Medical Center, Encinitas, California

**Senior Clinical Research Coordinator**                      **1997 to 2004**  
**Assistant to President**  
 Damluji Research Center, San Diego, California

**Volunteer – Intensive Care Unit**                                      **1996 to present**  
 Scripps Memorial Hospital La Jolla, California

**Senior Resident – General Surgery & Plastic Surgery**  
 Al Numan Hospital – Baghdad, Iraq                                      **1992-1996**

**Medical Doctor - Rural Area Hospital**                                      **1991-1992**

**Medical Doctor - Atomic Energy Organization**    **1989-1991**  
 Internal Medicine – Baghdad, Iraq

**Responsibilities:** Monitored hospital and all employees for radiation contamination. Conducted all follow up and treatment of those affected by Radiation. Conducted clinical trials in the Specialty Clinic.

### **Military Service**

Military Doctor – Battle field Surgeon                                      **1987-1989**  
 Iraq

### **Appointments**

Ministry of Health letters of recognition                      **1990, 1992 and 1996**  
 For Distinction and Excellence in patients  
 Treatment.

Medal of Honor - Ministry of Health - Iraq                                      **1996**

**CLINICAL RESEARCH TRIAL EXPERIENCE****ONCOLOGY:**

- 06/10/1996 Novartis Pharmaceutical, Letrozole (CGS 20267) Protocol-02  
**Breast Cancer**
- 06/26/1997 Novartis Pharmaceutical, Letrozole (CGS 20267) Protocol-025  
**Breast Cancer**
- 07/25/1997 Aronex Pharma; Protocol-AR-95-41, 356-006, **Cancer Pain**
- 11/06/1997 Algos Pharma; Protocol 49774-013, **Cancer Pain**
- 03/15/1998 Boehringer Ingelheim; **Antiemetic- Cancer Patient after chemotherapy**
- 09/20/1999 Laboratories IDDS; Protocol MSU93021/006; **Cancer Pain**
- 08/25/2000 G.D. Searle&Co; Protocol N91-00-02-079, **Cancer Pain**
- 03/19/2001 Smithkline Beecham; Protocol SKF-104864A/389,  
Topotecan, **Small Cell Lung Cancer**
- 02/25/2003 Luitpold Pharmaceuticals, Inc.; Protocol 1VEN02023  
**Iron Sucrose (Venofer) i.v., Anemia in Cancer Patients**
- 03/26/2003 Watson Laboratories, Inc.; Protocol FR01008,  
**Ferrlecit Anemia in Cancer Patients**
- 06/27/2003 GSK; Protocol EGF20002, phase II-oral GW572016,  
Advanced or Metastatic **Breast Cancer**

**CARDIOLOGY:**

- 03/01/1998 Dupont Pharma; Protocol # 754-010/; **in prevention of second Heart attack.**
- 05/26/1999 Novartis Pharma; AG, Value 405, **Hypertension.**
- 10/13/1999 Searle; Protocol 193-99-02-035, **Pain-After Coronary artery bypass surgery.**
- 07/12/2000 Alliance Pharma; Protocol OXHT-0170INT; **Coronary artery bypass surgery.**

- 07/21/2000 Bristol-Myers Squibb; Protocol CV137-120; **Hypertension.**
- 02/15/2001 Vantex CVC; Protocol # 2000-02, **Device.**
- 08/03/2001 ABBOT Laboratories; Protocol 2000-042/007, **Urokinase Occluded Central Venous Catheters (Safety/Efficacy)**

### **GASTROENTEROLOGY:**

- 04/02/1998 Janssen Pharma Research Foundation; Protocol-R 108512-UXA-13 – **Constipation.**
- 07/06/1998 Merck Research Laboratories; Protocol 119-010 **Heartburn.**
- 07/23/1998 Astra Merck; Protocol 193/18 / **Heartburn.**
- 08/28/1998 GlaxoWellcome; Protocol GR68755; **Irritable Bowel Syndrome.**
- 09/07/1999 GlaxoWellcome; Protocol #S3B20023, **Irritable Bowel Syndrome (women)**
- 09/14/1999 GlaxoWellcome, Protocol #S3B30013, **Irritable Bowel Syndrome (men)**
- 06/16/1999 TAP Holding; Protocol M98-890, **Heartburn.**
- 06/19/2000 Covance/AstraZeneca; EAZEE Protocol-267 – **Erosive Esophagitis**
- 03/28/2002 TAP Pharmaceutical; Protocol- M02-420 PACE, Efficacy of Lansoprazole 30 mg QD versus Esomeprazole In **GERD associated Heartburn**
- 05/16/2002 Forest Laboratories, Inc.; Protocol DEX-MD-02A Safety and efficacy of Dexloxyglumide in female patients with constipation predominant **Irritable Bowel Syndrome**
- 11/26/2001 Forest Laboratories, Inc.; Protocol- DEX-MD-02B Open Label of Dexloxyglumide 200 mg T.I.D., **Irritable Bowel Syndrome**
- 06/10/2002 TAP Pharmaceutical; Protocol- M02-409, Effect of Lansoprazole 30 mg QD versus Esomeprazole 40 mg QD on Erosive **Esophagitis**

- 01/08/2003 Solvay Pharmaceuticals, Inc.; Protocol S2413006  
Cilansetron in Diarrhea Predominant **Irritable Bowel Syndrome** Subjects.
- 06/17/2003 Solvay Pharmaceuticals, Inc.; Protocol S2413007  
Cilansetron in Diarrhea Predominant **Irritable Bowel Syndrome** Subjects.
- 07/29/2003 GSK- Protocol/ S3B30048- Alosetron in female patients with  
Severe diarrhea predominant **Irritable Bowel Syndrome**.
- 10/03/2003 Pain Therapeutics, Inc.; Low-Dose Naltrexone HCl in  
Male Patients with **Irritable Bowel Syndrome**.

**ORTHOPEDIC:**

- 04/29/1999 Parke-Davis; Protocol 1008-104, **Pain control (back pain)**
- 04/29/1999 Searle; Protocol-N93-99-02-028, **Pain - Arthroscopic Surgery**
- 03/25/2000 Purdue Pharma L.P, Protocol HMP-3003 - **Pain Control after Total Hip and knee surgery.**
- 05/12/2000 Knoll Pharma; Protocol-DO-132, **Pain-Orthopedic(Osteoarthritis)**
- 11/26/2000 Purdue Pharma L.P; Protocol OXY 4001 - **Pain Control after Total Hip and Knee Surgery.**
- 03/09/2001 Pharmacia Corporation; 542E-CVD-0042-029,  
LM/Fragmin.Total knee replacement surgery, **Deep Venous Thrombosis.**
- 05/20/2002 Sanofi-Synthelabo, Inc.; Protocol L-8229, Double blind intra-articular  
Injection of Hyalgan into the Glenohumeral joint (**shoulder pain**)
- 07/16/2001 Purdue Pharma L.P.; Protocol 4003 OXY,  
Usual Care in subjects with **Moderate to Severe Osteoarthritis,**  
**Pain** of Hip or Knee
- 08/29/2001 AAI Pharma Inc, Protocol; AAI-000396, Diclofenac Potassium  
Softgel 25 or 50 mg in the treatment of **Arthroscopic Knee  
Surgery Pain**
- 04/08/2002 Purdue Pharma L.P.; Protocol-HCD 2002, evaluate the  
Efficacy and safety of 15 and 30 mg extended release  
Hydrocodone (HCD) in patients for **Pain - Arthroscopic surgery**

09/16/2002 Pharmacia; Protocol E93-01-02-067, Parecoxib;  
**Post-Surgical Pain - Orthopedic Surgery, total knee replacement.**

05/05/2003 Merck& Co, Inc; Protocol 0301-0, Open Label-Rofecoxib  
50 mg; selected outpatient **Arthroscopy Procedures**

### **RESPIRATORY SYSTEM**

07/26/2000 ABBOT Laboratories-ABT-773, Protocol M00-219, **Respiratory Infections  
Chronic obstructive pulmonary disease.**

10/16/2000 ABBOT Laboratories-ABT-773, Protocol M00-216, **Respiratory Infections  
Chronic obstructive pulmonary disease.**

### **INFECTIOUS DISEASES**

10/06/2000 3M Pharmaceuticals/Protocol 1410-RESI, **Genital Herpes**

04/10/2002 3M Pharmaceuticals/ Protocol-1466-RESI, **Genital Herpes**  
Open Label of Topical Resiquimod (r-848) over 104 weeks

### **RENAL SYSTEM**

02/14/2002 SmithKline Beecham; Protocol-223412/020, Symptoms of  
**Urinary urgency and frequency with or without incontinence**

07/16/1997 Bayer Corporation; Protocol-D97-008; **Metabolic Disease**

---